Hyloris expects to expand its portfolio to around 30 candidates by 2024, bolstered by €50m in cash and cash equivalents as of the end of 2021.
Belgian value-added medicines company Hyloris Pharmaceuticals SA has outlined an ambitious growth strategy while announcing its financial and operational results for the full-year ending 31 December 2021. Its plans will be supported by its €50m ($55.4m) in cash and cash equivalents as of the end of the year.
These assets have left the company “well-capitalized to advance all current pipeline assets as planned and execute its current business plan,” with the expectation of expanding its
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
